Appointment

858 Therapeutics Appoints Srini Ramanathan as Chief Executive Officer

Nov 16, 2026 | By Kuldeep Jangid

858 Therapeutics Appoints Srini Ramanathan as Chief Executive Officer

858 Therapeutics, a biotechnology company developing new cancer treatments, has appointed Srini Ramanathan, Ph.D. as its new Chief Executive Officer.

SUMMARY

  • 858 Therapeutics appointed Srini Ramanathan as CEO.
  • He will lead the development of its cancer drug.
  • 858 Therapeutics develops cancer treatments.

He brings extensive experience in drug development, and clinical research as the company moves its PARG inhibitor ETX-19477 through clinical trials.

Dr. Jeffrey Stafford, the company’s founding CEO, will step down from the role and become Executive Chairman of the Board of Directors.

Dr. Ramanathan joins 858 Therapeutics with strong experience in leading clinical development programs, and moving new treatments through important stages. He takes on the role as the company advances its lead candidate, ETX-19477 a PARG inhibitor being developed to treat solid tumor's with specific DNA repair weaknesses. The drug is designed to be a potential first and best in class treatment.

Read More:Microsoft Pivots to AI Agents as Azure Hits $100B, Though Cash Flow Dips

Before joining 858 Therapeutics, Dr. Ramanathan served as Chief Development Officer at Aditum Bio and previously worked at Roivant, where he helped develop and guide portfolio companies. He has also held leadership roles at Horizon Therapeutics, AbbVie and Gilead Sciences, contributing to the development and approval of treatments in oncology, immunology and virology.

“Over the past seven years, Jeff’s leadership has been foundational in building 858 Therapeutics from the ground up and delivering on our mission to discover impactful medicines,” said Ali Behbahani, M.D., Partner at NEA and Board Director at 858 Therapeutics. “We are delighted that he will continue to shape 858's strategic direction as Executive Chairman while we welcome Srini to steer the company into its next phase of clinical growth.”

“On behalf of the entire Board, I want to thank Jeff for his outstanding contributions during his tenure as CEO,” said Clare Ozawa, Ph.D., Managing Director at Versant Ventures and Board Director at 858 Therapeutics. “In addition to his continued impact at 858, we are very excited for Jeff’s next role as CEO of a stealth Versant startup.”

About 858 Therapeutics

Founded in 2019, 858 Therapeutics is a clinical-stage biotechnology company developing treatments that target weaknesses in cancer cells DNA repair pathways. It's lead drug candidate, ETX-19477, is an oral medicine designed to target specific weaknesses in cancer cells linked to replication stress and DNA repair. ETX-19477 is currently being tested in a Phase 1/2 clinical trial involving patients with advanced solid tumors. The study is open label and taking place across multiple medical centres.

About 858 Therapeutics

Read More:GoGoMeds Appoints Harish Panchal as Chief Executive Officer

Recommended Stories for You